Kornimate/medical-research-clean huggingface dataset:
performances and safety of mucopilot, a digital tool for the unsupervised objective assessment of cystic fibrosis

Conditions: Cystic Fibrosis

Summary: the study aims to evaluate mucopilot, a smartphone application to measure objective data on lung function (cough and dyspnea tests), global exercise capacity (walking test) and patient-reported outcomes (pros) of patients with cystic fibrosis (cf). these data are collected during unsupervised digital tests performed in the patient's home environment between consultations. the primary objective is to demonstrate the correlation of the mucopilot digital tests at home (d1) with the results of their standard counterparts (d0) carried out in-clinic. a secondary objective is to determine the accuracy, reliability and reproducibility of tests results, as well as to study the test-retest of the pro. the study also aims to assess the safety, usability, and satisfaction of the solution. exploratory objectives include evaluating the relationship between mucopilot's scores and other standards such as fvc, fev1/fvc ratio as well as to explore the correlation with the cough monitoring with patient's perception. patients will be able to download mucopilot app. they will participate in 1 inclusion visit and 7 follow-up visits, scheduled at day 1, day 3, day 5, day 7, 1 month, 2 months, 3 months - 1 day. the study will include 70 cf patients and will be conducted in france.


Eligibility criteria:
inclusion criteria: * adult (≥ 18 years old) patients living with cystic fibrosis (cf) * enrolled in or benefiting of a social security program * having read the information sheet and signed the informed consent form * owning a personal smartphone which operating system (os) is equal or above 14 for ios (iphone) and 8 for android, and have access to a good internet connexion * able to read language in which the mobile application is available and able to understand pictograms on the application exclusion criteria: * history of lung transplantation * pregnant women and women who are breastfeeding * any medical condition that could interfere with the proper conduct and results of the study (investigator's judgement) * illiteracy in french * inability to use a smartphone or mucopilot application * persons under legal protection (i.e guardianship or curatorship) * participation in another clinical interventional study within 30 days prior to selection or current participation in another study that, in the opinion of the investigator, could interfere with the proper conduct and results of the study
development & validation of pregnancy specific pelvic floor rehab protocol

Conditions: Pelvic Floor Disorder; Pelvic Floor Muscle Weakness; Pelvic Floor Muscle Training; Pregnancy

Summary: pelvic floor weakness is very common facing by women during pregnancy. pfm weakness is recognized as one of the problems encountered in patients with urinary and fecal incontinence which have very negative impact on quality of life of patients. this project aims to design, implement, and validate a pelvic floor rehabilitation protocol specifically for pregnant individuals.

the review of existing literature undergoes the critical need for a pregnancy-specific pelvic floor rehab protocol to address the unique physiological and functional changes experienced during and after pregnancy. while current pelvic floor rehab approaches provide valuable insights, they often lack specific adaptations for the pregnant population, in first phase of study the protocol will be developed .the protocol will focus on preventing and managing pelvic floor dysfunction (pfd), such as urinary incontinence, pelvic organ prolapse, and pelvic pain, which are common during pregnancy. the program will incorporate evidence-based exercises, education, and lifestyle modifications, ensuring it is safe, effective, and adaptable to pregnancy. in second phase it will be validated and pilot testing will be done.

Eligibility criteria:
inclusion criteria: * diagnosed pelvic floor dysfunction. female participants experience pelvic floor symptoms such as incontinence, pelvic pain, or prolapse. no previous participation in a structured pelvic floor rehabilitation program within the last six months exclusion criteria: * pregnant women or those planning to become pregnant during the study period. * patients with neurological disorders affecting pelvic floor function (e.g., multiple sclerosis, spinal cord injury). * individuals with severe psychiatric conditions that might interfere with participation. * recent pelvic surgery within the last three months. * any contraindications to physical therapy or specific exercises included in the rehab program.
"study of halitosis in patients with advanced chronic periodontitis"

Conditions: Periodontal Disease; Halitosis; Periodontitis

Summary: the objective of this study was to evaluate whether short-term full mouth disinfection protocol could have a greater reduction in the levels of halitosis and volatile sulfur compound or not, when compared to quadrant-wise scaling and root planing

in recent years, several studies have shown that the levels of volatile sulfur compounds are higher in periodontitis patients. however, the relationship between periodontal disease and bad breath is still controversial. aspects that should be clarified include its relation to periodontitis severity, the influence of risk variables and the subject of the present research, that is treatment choice. to help clinicians and patients when deciding about mechanical periodontal therapy, 30 patients with advanced chronic periodontitis were selected from the periodontics clinic, dental school, pontiphical catholic university of minas gerais from april 2013 to may 2014. a complete periodontal clinical examination was performed and the following parameters were recorded: probing depth (pd), clinical attachment level (cal), bleeding on probing, plaque index, and tongue coating index. halitosis was assessed by using the organoleptic method and measurements of volatile sulfur compounds (vsc), including hydrogen sulfide (h2s) and methyl mercaptan (ch3sh) by using gas chromatography, at baseline and 90 days after non-surgical periodontal treatment. after periodontal clinical examination, individuals were randomly allocated to full-mouth scaling (fms) - completed within 24 hours - or to conventional quadrant-wise scaling and root planing (srp) - completed within 2 months. halitosis and sulfur gas levels were were statistically compared (mann-whitney and wilcoxon tests, p \< 0.05). for inter- and intra-group comparisons regarding categorical variables chi-square, mcnemar, and fisher exact tests were used. primary outcome was halitosis changing.

Eligibility criteria:
inclusion criteria: * age between 35 and 60 years * presence of at least 20 natural teeth * diagnosis of chronic periodontitis * halitosis * no smokers exclusion criteria: * smokers or former smokers * individuals diagnosed with diabetes and / or immunological disorders * pregnant or lactating / patients with removable partial dentures and / or fixed or removable orthodontic appliance * systemic use of antibiotics or anti-inflammatory in the last six months * need for prophylactic use of antibiotics for performing the treatment * regular use or use in the last six months of any kind of mouthwash * individuals who underwent periodontal treatment in the 6 months preceding the start of the study

Keywords: halitosis sulfur compounds periodontitis periodontal treatment
culinary medicine to enhance protein intake on muscle quality in older adults

Conditions: Sarcopenia

Summary: aging is associated with a decline in muscle mass, strength, and physical function, leading to muscle mass loss and weakness. these concerns can impact an individual's functional independence and quality of life (qol). dietary protein stimulates muscle protein growth. current studies suggest that optimal protein intake for older adults is greater than the recommended dietary allowance. barriers to consuming protein-rich foods in older adults include reductions in taste and smell, dentition, dexterity, and changes in living situation. therefore, nutritional interventions are needed to effectively improve eating behaviors, diet quality, and stimulate muscle growth and strength. these interventions will help prevent, manage, and promote muscle mass loss recovery. older adults may not be aware of their changing nutrient needs and therefore may lack the skills to prepare nutritionally adequate foods properly. cooking demonstrations, or culinary medicine (cm), can help teach healthy cooking to reduce potential red meat consumption barriers and improve community-dwelling older adults' dietary habits. thus, cm can be a novel strategy to improve diet quality in older adults and promote and augment at-home cooking. cm is an evidenced-base field that combines skills of preparing, cooking, and presenting food with the science of medicine. this field can help to accomplish potential eating behaviors and health outcome improvements. a tailored cm program can be an effective strategy that could reduce barriers in protein intake that will enable older adults to age well and productively.


Eligibility criteria:
inclusion criteria: * 65 years and older * physically active * able to cook for oneself * willing to complete two blood draws exclusion criteria: * \<65 years old * sedentary lifestyle * bleeding disorder * heart pacemaker * type 1 diabetics and type 2 diabetics taking insulin * current smokers * amputees

Keywords: culinary medicine muscle synthesis muscle strength protein intake
esketamine for prevention of depression after cytoreductive surgery in ovarian cancer

Conditions: Ovarian Cancer; Cytoreductive Surgery; Depressive Symptom

Summary: the goal of this clinical trial is to learn if intraoperative administration of esketamine would prevent or mitigate postoperative depressive symptoms after cytoreductive surgery in ovarian cancer. the main questions it aims to answer are: * whether a single low dose of esketamine administered would reduce the postoperative depressive symptoms three days after cytoreductive surgery in ovarian cancer? * whether a single low dose of esketamine administered would relief the postoperative sleep disturbance, postoperative recovery? researchers will compare the esketamine to a placebo (normal saline) to see if the esketamine works to reduce the postoperative depressive symptoms. participants will: * receive either 0.2 mg/kg esketamine or placebo infused intravenously after induction of general anesthesia. * the preoperative patient health questionnaire 9 (phq-9) scale was used to verify the symptoms suggestive of depression.


Eligibility criteria:
inclusion criteria: * undergoing cytoreductive surgery for ovarian cancer under general anesthesia * asa physical status i-iii * ages 18-80 years exclusion criteria: * patients taking anti-psychotic medications * contraindications to esketamine * language barrier * inability to provide consent
proton radiotherapy plus sorafenib versus sorafenib for patients with hcc exceeding san francisco criteria

Conditions: Carcinoma, Hepatocellular

Summary: this study is designed to determine whether proton beam radiotherapy plus sorafenib compared to sorafenib alone will produce the best results for treating patients with hepatocellular carcinoma.


Eligibility criteria:
inclusion criteria: 1. patients are candidates to receive both proton beam and sorafenib 2. patients with tumor burden that exceeds san francisco criteria exclusion criteria: 1. patients who are candidates for surgical resection 2. patients with tumor burden within milan and/or san francisco criteria 3. patients who have contraindication to receive proton 4. patients with contraindication to receive sorafenib including uncontrolled hypertension, coumadin treatment and prior intolerability to the drug 5. patients treated previously by any locoregional treatment 6. patients with prior liver transplant 7. patients with child class c 8. patients with model for end-stage liver disease (meld) score of \> 25 9. patients with other comorbid diseases that may impact survival 10. patients with ongoing alcohol intake 11. patients with active sepsis 12. patients with gastrointestinal bleeding within a week 13. patients unwilling to sign informed consent form 14. patients with history of noncompliance

Keywords: carcinoma, hepatocellular proton beam radiotherapy sorafenib
outcomes following phacoemulsification with 1.8 & 2.2mm incision: randomized clinical trial

Conditions: Cataract

Summary: cataract surgical techniques have significantly changed in recent years with the widespread adoption of smaller and smaller clear corneal incisions for phacoemulsification. microincision surgery has many advantages, including reduced surgically induced astigmatism, faster visual recovery, and reduced intra and postoperative inflammation. curently, microcoaxial phacoemulsification is being performed through 1.8 as well as 2.2 mm incisions. however, there is still a debate as to which is the best absolute incision size for microcoaxial cataract surgery. the aim of this study is to evaluate incision stability following microcoaxial phacoemulsification performed through 1.8 and 2.2 mm systems, as well as compare intraoperative performance and postoperative outcomes following microcoaxial phacoemulsification performed through these two incision sizes.

cataract surgical techniques have significantly changed in recent years with the widespread adoption of smaller and smaller clear corneal incisions for phacoemulsification. microincision surgery has many advantages, including reduced surgically induced astigmatism, faster visual recovery, and reduced intra and postoperative inflammation. in the recent times, microcoaxial phacoemulsification has gained popularity. the main advantage of this newer technique is that it uses the same methods as the conventional method but with smaller incisions. curently, microcoaxial phacoemulsification is being performed through 1.8 as well as 2.2 mm incisions. however, there is still a debate as to which is the best absolute incision size for microcoaxial cataract surgery. the aim of this study is to evaluate incision stability following microcoaxial phacoemulsification performed through 1.8 and 2.2 mm systems, as well as compare intraoperative performance and postoperative outcomes following microcoaxial phacoemulsification performed through these two incision sizes.

Eligibility criteria:
inclusion criteria: uncomplicated age related cataracts, no grade ii iii, iv (locs iii classification) - exclusion criteria: * ocular comorbidity, glaucoma, uveitis, shallow anterior chamber, maximal pupillary dilatation \ 25mm), previous ocular trauma or surgery, pseudoexfoliation, traumatic cataract, subluxated cataract

Keywords: microcoaxial phacoemulsification, 1.8mm, 2.2mm
automate music therapy for the management of behavioral disorders in nursing homes

Conditions: Alzheimer Disease; Major Neurocognitive Disorder

Summary: alzheimer disease is the most common neurodegenerative brain disease that causes cognitive impairment in the elderly but also behavioral and psychological symptoms. among these symptoms, agitation is one of the most dangerous because it put the patient and their caregivers in danger. sleep disorders can be the cause of many psychiatric symptoms leading directly or indirectly to agitation. music therapy is the non-drug therapy which has been shown to be the most effective in managing agitation and sleep disorders. with the mage protocol, the investigators propose to take care of behavioral disorders in severe alzheimer patients living in nursing home through sequences of music therapy (stimulation, relaxation) automatically initiated by an actigraph that will detect sleep disorders. these subjects will be exposed for 2 weeks over a month. behavioral and sleep disorders will be evaluated objectively by actigraphy but also by standardized scales, as the others neuropsychiatric symptoms found classically in this disease. thanks to this project, the investigators hope to improve the quality of life of these patients by preventing them from putting themselves in danger, by reducing their neuropsychiatric symptoms and their use of medication, which has often deleterious side effect and also by reducing the workload of caregivers.


Eligibility criteria:
inclusion criteria: * age ≥ 60 years old * male or female * patients with a diagnosis of alzheimer disease according to the criteria of nincds-adrda or typical or atypical alzheimer disease * mmse \< 20 * patient residing in nursing home * voluntary, written and informed consent of the patient himself or its legal representative (guardian/curator) * affiliation to a social security system exclusion criteria: * prescription of a new psychotropic treatment (hypnotic, anxiolytic, antidepressant, antipsychotic) in week prior to the evaluation * hearing loss preventing the patient from responding perfectly to the therapeutic solutions provided
epidemiology of diverticulitis in lung transplant recipients

Conditions: Lung Transplant Recipients; Diverticulitis

Summary: the purpose of this study is to assess incidence, treatment modalities and outcome of complicated and uncomplicated diverticulitis in highly immunosuppressed lung transplant recipients (ltrs) in order to establish improved treatment strategies in this high risk patient collective.

sigmoid diverticulitis is common and potentially problematic in immunosuppressed patients. the choice between conservative and surgical treatment for uncomplicated diverticulitis remains unclear, as well as the value of the hartmann's procedure (hp) for complicated diverticulitis. our aim is to assess incidence, treatment options and outcome of complicated and uncomplicated diverticulitis in highly immunosuppressed lung transplant recipients (ltrs) by retrospectively analysing our prospective database of around 400 lung transplant recipients transplanted between 1992 and 2013.

Eligibility criteria:
inclusion criteria: * lung transplant recipient * diverticulitis exclusion criteria: * none

Keywords: lung transplant recipients diverticulitis immunosuppression
contingency outcomes in prolonged exposure

Conditions: Posttraumatic Stress Disorder; Substance Use Disorder

Summary: the aim of this research is to assess whether contingency management is effective in improving treatment adherence in substance use disordered (sud) patients with comorbid ptsd. although prolonged exposure therapy (pe) is the gold standard treatment for ptsd, the few studies of this treatment in substance users have shown poor adherence. contingency management is a well-established approach that could be used to enhance adherence to pe. from a consented sample of 125 opioid-dependent and methadone-treated patients at addiction treatment services, an intent-to-treat sample of 62 patients with co-occurring current ptsd will be offered pe. half of the 62 participants will be randomly assigned to a prolonged exposure with contingency management (pe+cm) condition that provides monetary-based incentives for attending the pe therapy sessions. the comparison condition will be assigned to a prolonged exposure (pe) condition without the attendance incentives intervention. the pe sessions will be scheduled once per week for 12 weeks, with a 12-week follow-up. groups will be compared primarily on adherence to the pe schedule, improvement in ptsd symptoms, and rates of drug use (urine specimens, self-reported use). the study's three primary aims are to 1) evaluate the efficacy of adding voucher-based attendance incentives to pe for ptsd to increase adherence in sud patients in a methadone treatment program; 2) evaluate the efficacy of adding voucher-based attendance incentives to pe for ptsd to reduce ptsd symptoms in sud patients; and 3) evaluate the effect of pe for ptsd on rates of drug use in sud patients.


Eligibility criteria:
inclusion criteria for phase i (evaluation): * positive screen for ptsd, as determined by score on the mpss-r * methadone maintenance for at least 4 weeks (to help ensure initial stabilization on methadone) * at least 18 years of age inclusion criteria for phase 2 (treatment): * confirmation of current ptsd based on the clinician-administered ptsd scale * no psychiatric contraindications to pe (e.g., current suicidal/homicidal intent) * clear memory for the traumatic event (e.g., flashbacks or re-experiencing the event) * interest in receiving pe * agree to sign release of information for any current psychiatric treatment providers outside of ats * agree to delay taking daily methadone dose on exposure therapy days until after session * no history of prior exposure-based therapy for ptsd * agree to audiotaping of therapy sessions exclusion criteria: * pregnancy * acute medical problem that requires immediate and intense medical management (e.g., aids defining illness; active tuberculosis) * presence of a formal thought disorder, delusions, hallucinations, or imminent risk of harm to self or others

Keywords: ptsd prolonged exposure comorbidity treatment methadone maintenance substance use disorder
empiric pulsed field pulmonary vein isolation during atrial tachycardia ablation in adults with congenital heart disease

Conditions: Atrial Fibrillation; Atrial Tachycardia; Atrial Flutter; Congenital Heart Disease; Pulmonary Vein Isolation; Pulsed Field Ablation; Catheter Ablation

Summary: this is a prospective, single-arm intervention trial whereby we will test the safety and efficacy of performing pulmonary vein isolation (pvi) using pulsed field ablation (pfa) in adult patients with congenital heart disease (chd) who are presenting for atrial tachycardia (at) ablation.


Eligibility criteria:
inclusion criteria: * adult patients (\>= 18 years of age) with repaired or unrepaired congenital heart disease and a history of sustained (\>30 seconds) at exclusion criteria: * history of sustained af and/or previous catheter or surgical pulmonary vein isolation.

Keywords: atrial fibrillation atrial tachycardia atrial flutter pulsed field ablation congenital heart disease adult congenital heart disease pulmonary vein isolation catheter ablation
study to evaluate safety and efficacy of asc42 combined with etv and peg-ifn α-2a in subjects with hbv

Conditions: Hepatitis B, Chronic

Summary: this is a phase2, randomized, single-blind, placebo controlled and multi-center study in adults with chronic hepatitis b virus. the study is aimed at evaluating efficacy and safety of asc42 in combination with entecavir and pegylated interferon α-2a in subjects with chronic hepatitis b virus.


Eligibility criteria:
inclusion criteria: * 18-65 years old (including 18 and 65 years old); * chronic hbv infection confirmed by serological, etiological and clinical diagnosis (hbsag positive for more than 6 months); * hbv-dna negative after nucleoside (acid) treatment; * laboratory test values meet the following requirements : * liver function : ast, alt ≤ 3×uln; serum total bilirubin≤2×uln; direct bilirubin≤1.5×uln; serum albumin≥35 g/l (blood collection is not within 2 weeks before transfusion of albumin); * hematology: white blood cell count\>3.0×109/l, anc\>1.5×109/l; platelet\>1×uln; hemoglobin 120g/l. (no blood transfusion (including transfusion of red blood cells and platelets) and epo, tpo, leukocyte-stimulating factor were required within 2 weeks before blood collection) ; * renal function: serum creatinine≤1×uln; * thyroid function: tsh and t4 in normal range or thyroid function can be completely controlled ; * determination of serum immunoglobulin : igm≤uln; * coagulation function: international normalized ratio: inr≤1×uln; exclusion criteria: * chronic hbv with unexplained portal hypertension; * subjects with liver cancer or serum afp \>1×uln; * previously received fxr therapy;

Keywords: hepatitis b, chronic asc42